上市捷报 | 沙利文助力美中嘉和医学技术发展集团股份有限公司成功赴港上市(2453.HK)

Meizhong Jiahé Medical Technology Development Group Co., Ltd. (Stock Code:2453.HK) on2024year1month9The company successfully listed on the main board of the Hong Kong capital market on [date]. It is a provider of oncology medical services in China, offering comprehensive oncology medical services to cancer patients through its healthcare institutions. At the same time, it provides services such as sales and installation, management and technical support, and operating leases of oncology-related medical equipment and software to corporate clients. Frost & SullivanFrost & Sullivan,Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') provides exclusive industry advisory services for the listing of Meizhongjiahé Medical Technology Development Group Co., Ltd. We hereby extend our warmest congratulations on its successful listing.

Meizhong Jiahé Medical Technology Development Group Co., Ltd. (hereinafter referred to as 'Meizhong Jiahé') was established in2024year1month9The company plans to go public on the 1st of July3,942.0210,000 sharesHstocks, among which90%For international distribution,10%The issue price per share for public offering14.28HK$, with the net amount of raised funds being approximately5.03HK$10 billion.

During the Hong Kong listing process, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support, and highlight the issuer's competitive advantages, assisting the issuer, investment banks, and other intermediaries in completing the relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business, and other important sections), helping the issuer communicate with the Hong Kong Stock Exchange and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on various industry-related issues from the Hong Kong Stock Exchange.

Investment highlights

The company is a leading provider of tumor treatment and precision radiotherapy in China;

The company strategically locates its own medical institutions in economically developed regions of China;

The company possesses medical technology, equipment, and professionals for cancer diagnosis and precision radiotherapy;

The company leverages integrated oncology-related services to serve the enterprise customer network;

The company has medical professionals and a visionary management team.

According to a report by Frost & Sullivan, by2022annual report, company

Ranked fifth in terms of revenue in the private oncology healthcare service market in China;

It ranks second in the number of its own private oncology medical institutions or the number of private medical institutions it administers;

It ranks second in the number of radiotherapy equipment units it operates or manages on its own;

Ranked second in terms of revenue in China's cancer treatment support service market.

Overview of China's Oncology Medical Service Market

The number of cancer patients in China has decreased from2016The year's promise4.1Growth from one million cases2022year4.8One million cases, estimated2026Will reach in5.3One million cases.2022In [year], the number of newly diagnosed cancer patients and cancer-related deaths in China accounted for approximately23.8%and cancer-related deaths26.9%.

Currently, the supply of oncology medical resources in China is still falling short of demand. With the continuous release of demand for cancer treatment, it will drive further growth in China's oncology medical service market. In particular, private oncology institutions can leverage their advantages, such as cancer diagnosis and treatment concepts obtained through international cooperation and systematic training, to provideMDTAdvanced treatment methods such as services and precision radiotherapy meet the diverse needs of patients, driving the development of the private tumor medical service market.

In terms of revenue, the market scale of oncology medical services in China2016year2,656RMB billion growth to2022year4,951yuan, with a compound annual growth rate of10.9%estimated2026Will reach in7,687yuan,2022Year-end2026The compound annual growth rate for the year is11.6%The market scale of private tumor medical services in China has grown from2016Renminbi in [year]189RMB billion growth to2022Renminbi in [year]530Yuan billion, expected2026RMB will reach1,092yuan,2022Year-end2026The compound annual growth rate for the year is19.8%The growth rate is higher than the entire tumor medical service market.

The competitive landscape of the private tumor medical service market in China

The private oncology healthcare industry in China is highly fragmented, according to a report by Frost & Sullivan.2022Year, China before5Proportion of the market held by large private oncology healthcare service providers6.5%Among them, the market share of Meizhongjiahe is0.5%.

Market Overview of Precision Radiotherapy and Proton Therapy

Precision radiotherapy is an advanced cancer treatment method that directly and precisely releases effective but controlled radiation energy into tumor tissue by redesigning the use of radiation energy. It significantly improves the efficacy of radiotherapy while reducing side effects and risks. Precision radiotherapy mainly includes three-dimensional conformal technology and intensity-modulated radiotherapy (IMRT), Volume Rotation Adaptive Intensity Modulation (IGRT), Stereotactic RadiosurgerySRT) and proton therapy.

2022In [year], the precision radiotherapy market in China accounted for approximately74.0%Driven by the advancement of precision radiotherapy technology and the increasing penetration rate, the market scale of precision radiotherapy in China, calculated based on revenue, has grown from2016Renminbi in [year]182RMB billion growth to2022Renminbi in [year]410yuan, with a compound annual growth rate of14.5%are expected to be2026RMB reached741yuan,2022Year-end2026The compound annual growth rate for the year is15.9%.

Proton therapy, as one of the precision radiotherapy techniques, has a characteristic energy distribution curve known as the Bragg peak. Therefore, it is possible to control the proton beam to release its maximum energy at the tumor tissue, achieving the best therapeutic effect while minimizing damage to surrounding healthy tissues.

Currently, there are very few proton centers in operation in China, and the market for proton therapy in China is still in its infancy. With the increase in the number of proton centers, advancements in proton therapy technology, the expansion of service capabilities at individual proton centers, and the continuous improvement in people's understanding of radiotherapy, the market size is expected to increase significantly in the future. In terms of revenue, the market size of proton therapy in China is calculated as2016Renminbi in [year]183.8Rise from one million to2022Renminbi in [year]319.2One million yuan, with a compound annual growth rate of9.6%; is expected to be available in2026RMB reached5,313.8One million yuan,2022Year-end2026The compound annual growth rate for the year is102.0%.

Overview of China's Cancer Treatment Support Service Market

Cancer treatment support services mainly focus on helping medical institutions establish, operate, and optimize radiotherapy and imaging diagnostic facilities. There are two types of services, namely offline services and cloud platform services. Offline services mainly include(1)Supply chain services, such as sales and leasing of equipment; and(2)Technical support services, such as personnel training and academic research. The cloud platform integrates core resources including medical expertise, information technology, and supply chain management to support the operational efficiency and healthcare standards of medical institutions.

In terms of revenue, the market scale of cancer treatment support services in China is2016Renminbi in [year]49RMB billion growth to2022Renminbi in [year]70yuan, with a compound annual growth rate of6.2%With the increasing demand for balanced distribution of medical resources, China's cancer treatment support service market is expected to2026RMB reached97yuan,2022Year-end2026The compound annual growth rate for the year is8.6%.

In the healthcare services sector, Frost & Sullivan has served companies such as Jinxin Reproductive Medicine Group, China Resources Healthcare Group, Harmony Medical Group, RuiCi Healthcare Group, Desvika Medical Group, Clear Medical Group, Chaopu Eye Hospital, and Ludaopei Medical Group.

Click at the end of the article

Read the original text

View the full prospectus of Meizhongjiahe

Frost & Sullivan integrates the globe63years of consulting experience,26Frost & Sullivan wholeheartedly serves the booming Chinese market, with a global perspective, helping clients accelerate their business growth, and achieving benchmark positions in industry growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listing cases include: WuXi AppTec (2268.HK), Anuo MedicineNASDAQ:ANL), Neusoft Xikang （9686.HK), Youzhiyou2496.HK), Yiming Angke 1541.HK ), Colombo Bay6 990.HK), LaiKai Medicine 2105.HK), Kedite Group2487.HK), Lvz Bio2480.HK), Meis Health 2415.HK), Yaohua MedicinePHECR), Zhongjin Medical （NASDAQ:ZJYL), Yisheng Biology NASDAQ:YS ), Beautiful Countryside 2373.HK), Kangfeng Biology6922.HK), Bao'an Biology6955.HK), Ideasight1244.HK), Meihao Medical1947.HK), Gaoshi Medical (2407.HK), Lepu Xintai2291.HK), Genstar Biotech9877.HK), HealthyuanJCARE.SW), Leopu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leopu Biology2157.HK), Clear Medical1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital (2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature Medicine (UPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Scientific & Pharmaceutical2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. According to the number of submission items, Frost & Sullivan's healthcare team has gone to Hong Kong for medicalIPO listingMaintain an absolute leading position,2018till2023Year after year, it has always ranked first in market share.

since2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely referenced in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Zhongyan Co., Ltd.688716.SH), Zhejiang Rongtai603119.SH), OptoGrid Technology 688450.SH ) , Hybrid Integration688249.SH), Wuxi Rilian688531.SH), Maolai Optics688502.SH), Kangwe Century688426.SH), coastal protein688137.SH), Novartis HealthCare (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.